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ORIGINAL ARTICLE
Two-stageGenome-wideMethylation Proﬁling in Childhood-onset
Crohn’s Disease Implicates Epigenetic Alterations at the
VMP1/MIR21 and HLA Loci
Alex T. Adams, MBChB,* Nicholas A. Kennedy, MBBS,* Richard Hansen, PhD,† Nicholas T. Ventham, MBBS,*
Kate R. O’Leary, BSc,* Hazel E. Drummond, BSc,* Colin L. Noble, MD,* Emad El-Omar, PhD,†
Richard K. Russell, PhD,‡ David C. Wilson, MD,§ Elaine R. Nimmo, PhD,* Georgina L. Hold, PhD,†
and Jack Satsangi, DPhil*
Background: As a result of technological and analytical advances, genome-wide characterization of key epigenetic alterations is now feasible in
complex diseases. We hypothesized that this may provide important insights into gene-environmental interactions in Crohn’s disease (CD) and is
especially pertinent to early onset disease.
Methods: The Illumina 450K platform was applied to assess epigenome-wide methylation proﬁles in circulating leukocyte DNA in discovery and
replication pediatric CD cohorts and controls. Data were corrected for differential leukocyte proportions. Targeted replication was performed in adults
using pyrosequencing. Methylation changes were correlated with gene expression in blood and intestinal mucosa.
Results: We identiﬁed 65 individual CpG sites with methylation alterations achieving epigenome-wide signiﬁcance after Bonferroni correction
(P , 1.1 · 1027), and 19 differently methylated regions displaying unidirectional methylation change. There was a highly signiﬁcant enrichment of
methylation changes around GWAS single nucleotide polymorphisms (P ¼ 3.7 · 1027), notably the HLA region and MIR21. Two-locus discriminant
analysis in the discovery cohort predicted disease in the pediatric replication cohort with high accuracy (area under the curve, 0.98). The ﬁndings
strongly implicate the transcriptional start site of MIR21 as a region of extended epigenetic alteration, containing the most signiﬁcant individual probes
(P ¼ 1.97 · 10215) within a GWAS risk locus. In extension studies, we conﬁrmed hypomethylation ofMIR21 in adults (P ¼ 6.6 · 1025, n¼ 172) and show
increased mRNA expression in leukocytes (P , 0.005, n ¼ 66) and in the inﬂamed intestine (P ¼ 1.4 · 1026, n ¼ 99).
Conclusions: We demonstrate highly signiﬁcant and replicable differences in DNA methylation in CD, deﬁning the disease-associated epigenome. The
data strongly implicate known GWAS loci, with compelling evidence implicating MIR21 and the HLA region.
(Inﬂamm Bowel Dis 2014;20:1784–1793)
Key Words: Crohn’s disease, Epigenetics, MIR21
T he last decade has seen tremendous success in identifyinggenetic loci associated with inherited susceptibility to Crohn’s
diesease (CD), with 140 loci identiﬁed in the most recent GWAS
meta-analysis.1 However, these determinants collectively explain
only an estimated 13.6%1 of disease variability, and the biological
variation each confers is unclear. The importance of noninherited
factors in pathogenesis has been highlighted by studies on the
increasing incidence of CD, especially in children,2,3 and in the
developing world,4,5 and by a greater understanding of the effects
of gut microbiota and diet on risk.6,7 A critical objective for CD
research is to characterize the interaction between genetic and
environmental factors.
Epigenetic alteration has emerged as a potential mechanism
through which these interactions may occur.8 Developments allow-
ing rapid assaying of cytosine methylation at nearly 5 · 105 posi-
tions, and insights into confounding effects in study design9 have
provided the impetus to build on promising pilot data from previous
generation technology to allow epigenome-wide association studies
(EWAS) to become a valuable complement to the more mature
GWAS.10 Epigenome mapping has been used to identify DNA
regulatory elements, explore cancer biology, and provide a growing
body of ﬁndings in complex diseases, such as rheumatoid arthri-
tis,11 multiple sclerosis,12 type 2 diabetes, and obesity.13,14
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Although the relationship between methylation and gene
expression and function is incompletely understood, relevant
modifying inﬂuences include age, ethnicity, smoking, gut micro-
biota, and diet.15–18 DNA-binding factors can directly inﬂuence
methylation, and in turn, altering methylation can directly inﬂu-
ence expression.19,20 We hypothesized that identiﬁcation of
altered levels of methylation, which are signiﬁcantly associated
with disease state, whether predating or following disease, offers
the potential for discovering new pathways integral to the disease
process and for predicting disease status.
MATERIALS AND METHODS
Study Design
Illumina 450k DNA methylation analysis was performed
separately in 2 pediatric cohorts (see Table, Supplemental Digital
Content 1, http://links.lww.com/IBD/A557 that contains demo-
graphic data for pediatric cohorts). Patients in the ﬁrst cohort were
treatment-naive, newly diagnosed CD cases. Patients in the sec-
ond cohort were children with an established diagnosis of CD.
Both cohorts used symptomatic controls, which were investigated
by colonoscopy, but in whom no pathology or abnormality was
discovered at initial investigation or subsequently. Linear discrim-
inant analysis (LDA) was applied to data generated in the discov-
ery cohort to identify biomarker candidates, which were then
tested in the replication cohort.
As the 2 pediatric stages were of similar design and showed
strong replication, they were amenable to a single joint analysis,
an approach recommended for suitable data sets9 because of the
increase in power it gives in discovering CpG sites with disease-
associated methylation changes. Seven of the most signiﬁcant
CpG sites implicated by the combined pediatric analysis were
assessed by pyrosequencing in an adult cohort with established
CD, and disease-associated expression changes were explored
(Fig. 1A).
Pediatric Patient Selection and Ethics
Pediatric samples were collected from centers across
Scotland. The Bacteria in Inﬂammatory bowel disease (IBD) in
Scottish Children Undergoing Investigation before Treatment
(BISCUIT) study provided peripheral blood leukocyte DNA for
the discovery cohort from 18 treatment-naive newly diagnosed
patients and 18 matched nondiseased controls from Aberdeen,
Glasgow, and Dundee. Controls had been rigorously investigated
for gastrointestinal symptoms but did not have or subsequently
develop any organic gastrointestinal pathology, including IBD.21
The replication cohort comprised DNA samples from 18 children
with established CD supplied by the Paediatric-onset IBD Cohort
and Treatment Study (PICTS),22 analyzed against a second set of
18 controls from the BISCUIT study. Within both cohorts,
patients and controls were matched for age and gender. The
BISCUIT study was approved by the North of Scotland Research
Ethics Committee (09/S0802/24) and PICTS by ethics committees
FIGURE 1. A, Schematic representation of study design, n ¼ ratio of CD samples to control samples. B, Log fold-change (log2 mean methylation in
CD/mean methylation in controls) for all probes with nominally signiﬁcant (uncorrected P, 0.05, n ¼ 3620) methylation changes in both pediatric
cohorts. Data are binned; colors of shorter wavelength indicate higher frequency. C, A 50 kb of genomic regions are more likely to contain GWAS
SNPs for IBD or CD if they also contain more signiﬁcant disease-associated methylation changes (P ¼ 3.66 · 1027). D, Manhattan plot of disease-
associated methylation changes; horizontal line corresponds to signiﬁcance after Bonferroni correction.
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at participating centers (Edinburgh, Glasgow, Aberdeen, and
Dundee—LREC 2002/6/18). Written informed consent was ob-
tained from the parents of all participating children. Informed assent
was also obtained from older children capable of understanding the
nature of the study. Demographics for both cohorts are in Table,
Supplemental Digital Content 1, http://links.lww.com/IBD/A557.
Genome-wide Methylation Proﬁling
Peripheral blood leukocyte DNA was bisulﬁte converted and
analyzed using the Illumina Human Methylation 450k platform
(Illumina, San Diego, CA)23 with cases and controls distributed
across chips. Probes were ﬁltered to remove any with a detection
P value of$0.01, those from sex chromosomes, and those that had
single nucleotide polymorphisms (SNPs) with a minor allele fre-
quency of $0.01 in the European population in the 1000 Genomes
Project24 within CpGs assayed by the array. Samples were removed
if there was a gender mismatch or if more than 5% of probes failed.
Data were corrected using background removal and
quantile normalization in the lumi R package25,26 followed by beta
mixture quantile dilation.27 Batch effects were controlled for using
ComBAT.28
Differential leukocyte counts from the same day that DNA
samples taken were available for 24 patients and 19 controls.
Linear models were created for all Illumina 450k probes and
disease status in these samples. Probes were selected, which had
F test with P values ,1028 but a P value for disease association
of .0.05. Combinations of 100 probes were tested, and the best
probe set was used to predict the differential cell counts for sam-
ples without measured differential leukocyte counts. This model is
similar to that described by Houseman et al.29
Analysis of the methylation status of cases versus controls
was performed using limma30 in R using linear modeling of beta
values with measured or predicted neutrophil, other granulocyte,
lymphocyte, and monocyte numbers as covariates.
The Benjamini–Hochberg false discovery rate (FDR)31 was
calculated for each probe, with a FDR corrected P ,0.05 used to
deﬁne signiﬁcance in analysis of broader methylation patterns, such as
identifying differentially methylated regions. For signiﬁcance of indi-
vidual probes, the more conservative Bonferroni correction was used.
Differently Methylated Regions
Differently methylated regions (DMRs) were deﬁned using
a reimplementation of the probe lasso DMR-calling technique used
by the ChAMP pipeline32 in R. This deﬁned a DMR as 3 or more
sequential probes with signiﬁcant (FDR adjusted P , 0.05) unidi-
rectional methylation changes falling within the lasso distance
threshold. The distance threshold uses a base size of 2 kb, modiﬁed
based on the methylation patterns of local genomic features.33
Replication of Methylation Findings in Adults
Twenty whole-blood DNA samples from adults with CD were
recruited from gastroenterology clinic while their disease was
quiescent, with 20 healthy controls collected during the same time
period (LREC 2000/4/192). In addition, methylation changes in
VMP1/MIR21 were replicated in an extended adult replication cohort
of 87 adults with CD and 85 healthy controls (see Table, Supple-
mental Digital Content 2, http://links.lww.com/IBD/A558 that con-
tains demographic data), of which the smaller group was a subset.
DNA was bisulﬁte converted with EZ-96 DNA Methyla-
tion Kits (Zymo Research, Irvine, CA), assays were designed
using PyroMark Assay Design Software (version 2.0.1.15;
Qiagen, Dusseldorf, Germany) and primers (see Table, Supple-
mental Digital Content 3, http://links.lww.com/IBD/A559 that
contains primer sequences) were ordered from Sigma-Aldrich
(St. Louis). Sequencing was performed on a PyroMark Q96 ID
machine (Qiagen) and analyzed in R v3.0.1.
VMP1 and MIR21 Expression
MIR21 primary transcript (pri-miR-21, primer details in
Table, Supplemental Digital Content 3, http://links.lww.com/
IBD/A559) was assayed by qPCR, with all patients and controls
giving written, informed consent (LREC 06/S1101/16, LREC
2000/4/192). Suitable patients with CD were prospectively re-
cruited from gastroenterology clinic and endoscopy lists, and
healthy controls were recruited from volunteers. Blood samples
were taken using a 21-gauge butterﬂy needle and 9 mL K3 EDTA
vacuette (Greiner, Germany) and stored at 48C for up to 2 hours.
Total RNA was then extracted from 1.5 mL whole blood using
QIAamp RNA blood mini kit (Qiagen) and stored at 2808C.
cDNA was converted using SuperScript Vilo cDNA synthesis kits
(Invitrogen, Carlsbad) and analyzed on a Corbett Rotor-Gene
6000 (Qiagen) with DyNAmo Flash SYBR green reagent
(Thermo Scientiﬁc, Waltham). Expression of pri-miR-21 was nor-
malized to reference gene TBP, (primer details in Table, Supple-
mental Digital Content 3, http://links.lww.com/IBD/A559) after
initial optimization against 4 reference genes (GAPDH, TBP,
SDHA, and ACTB) and analyzed by the DDCt method in R.
Expression in inﬂamed and uninﬂamed intestinal biopsies from
patients with CD, ulcerative colitis, and healthy controls was
assessed in previously reported microarray data.34
Linear Discriminant Analysis
LDA of methylation beta values in the pediatric discovery
cohort was used to create biomarkers for the presence of CD, using
the LDA function in the R package “MASS.”35 All probes with
FDR adjusted P values ,0.05 in the discovery cohort (see Table,
Supplemental Digital Content 4, http://links.lww.com/IBD/A560
that lists pediatric discovery results with FDR adjusted P , 0.05)
were used as covariates, regardless of performance in the replica-
tion cohort, with each model including 2 probes. Models were
tested using the pediatric replication cohort methylation beta values.
GWAS Colocalization
For range thresholds between 25 kb and 4 Mb, the lowest
P value within range of each GWAS SNP for CD or IBD1 was
compared by Wilcoxon rank sum test to 1000 randomly selected
bins of the same genomic size, matched for probe density.
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GO Term Enrichment Analysis
The R package GOseq36 was used as described by Geeleher
et al37 to correct for bias introduced by the variation in Illumina 450k
probes per gene and analyze gene ontology (GO) term enrichment.
The number of probes sharing each gene symbol annotation and
whether that annotation covers at least one differentially methylated
probe (FDR corrected P , 0.05) was used to create a probability
weighting function, used in the GO term enrichment analysis.
RESULTS
Pediatric Illumina 450k
Nine probes with FDR corrected P , 0.05 were identiﬁed
in the discovery cohort, 8 of which achieved nominal signiﬁcance
in the replication cohort (see Table, Supplemental Digital Content
4, http://links.lww.com/IBD/A560 that lists pediatric discovery
results with FDR adjusted P, 0.05). Correlation between cohorts
was high, with 89% of probes reaching nominal signiﬁcance in
both cohorts showing the same direction of change (Fig. 1B).
Combined analysis of the 2 cohorts identiﬁed 1319 probes
with signiﬁcant FDR adjusted P values. Of these, 65 CpGs (Table 1,
Fig. 1D) retained epigenome-wide signiﬁcance after the more strin-
gent Bonferroni correction for multiple testing. At these probes,
there were absolute differences in mean methylation between CD
and control groups of up to 16% (mean 6%), with 89% of probes
showing hypomethylation in CD. Methylation variance in CD at
these probes was greater than controls in 65%, 53% of which
differences were statistically signiﬁcant (17% for probes where
variance was greater in controls). The mean ratio of variances
between CD and control were 2.4 and 1.4 for probes where CD
or control, respectively had the greater variance.
Nineteen DMRs were identiﬁed (Table 2) from the 1319
probes with signiﬁcant FDR adjusted P values. These regions
involve several genes in pathways relevant to CD including
TNF within the HLA region, MIR21, Toll-like receptor signaling
(TOLLIP), and apoptosis (VMP1, PRF1 and DIABLO).
Colocalization of signiﬁcant Illumina 450k methylation
changes with GWAS SNPs was found across distance thresholds
between 25 kb and 4 Mb, with peak correlation between 50 kb (P¼
3.66 · 1027) and 100 kb (P ¼ 2.41 · 1027) in line with previously
published work,38 (Fig. 1C). This relationship remained signiﬁcant
if VMP1/MIR21 was excluded from analysis.
GO term analysis found 170 signiﬁcantly enriched terms
(see Table, Supplemental Digital Content 6, http://links.lww.com/
IBD/A562 that lists all enriched GO terms) in the combined pedi-
atric data, including terms related to NF-kB signaling, apoptosis,
and the JAK-STAT cascade (FDR corrected P values 6.32 ·
1026, 2.31 · 1024 and 3.23 · 1023).
Adult Replication with Pyrosequencing
Pyrosequencing assays were designed for a series of 7 regions
corresponding to signiﬁcant disease-associated methylation changes
in the combined pediatric Illumina 450k data. Methylation changes
were assayed in a group of 20 adults with CD and 20 controls with
resultant P values between 0.004 and 2 · 1025 (Fig. 2B). As with
TABLE 1. The 15 Most Signiﬁcant Individual Probes from the Combined Analysis of the Combined Pediatric Data
Probe Details Discovery Cohort Replication Cohort Combined Analysis
Probe ID Chr Coordinatea Gene Dbb P Db P Db P Bonferroni
cg12054453 17 57915717 VMP1 20.15 2.19 · 10210 20.12 1.55 · 1025 20.13 1.97 · 10215 8.86 · 10210
cg17501210 6 166970252 RPS6KA2 20.11 1.17 · 1028 20.10 3.73 · 1026 20.11 4.47 · 10215 2.01 · 1029
cg12992827 3 101901234 — 20.12 3.82 · 1029 20.08 5.14 · 1025 20.10 1.59 · 10213 7.13 · 1028
cg16936953 17 57915665 VMP1 20.17 9.11 · 10210 20.14 9.25 · 1025 20.16 2.65 · 10213 1.19 · 1027
cg04389058 3 57041402 ARHGEF3 20.08 3.32 · 1028 20.06 4.69 · 1025 20.07 1.44 · 10212 6.48 · 1027
cg02560388 2 11969958 — 20.04 1.93 · 1026 20.05 1.60 · 1025 20.04 8.45 · 10212 3.80 · 1026
cg00382138 4 110723299 CFI 20.08 1.88 · 1026 20.08 2.60 · 1025 20.07 3.27 · 10211 1.47 · 1025
cg01671681 3 155421735 PLCH1 20.05 4.43 · 1026 20.05 5.23 · 1025 20.05 4.52 · 10211 2.03 · 1025
cg19821297 19 12890029 — 20.08 3.35 · 1026 20.08 7.09 · 1025 20.08 1.91 · 10210 8.60 · 1025
cg27049094 2 75067716 HK2 0.07 9.03 · 1026 0.07 8.62 · 1026 0.07 2.04 · 10210 9.18 · 1025
cg27310092 1 151945663 — 20.05 2.67 · 1026 20.07 2.56 · 1025 20.06 2.54 · 10210 0.0001
cg01059398 3 172235808 TNFSF10 20.07 9.77 · 1026 20.07 1.63 · 1024 20.07 3.28 · 10210 0.0001
cg18181703 17 76354621 SOCS3 20.09 3.05 · 1025 20.09 2.43 · 1025 20.09 4.56 · 10210 0.0002
cg01726890 7 38370874 — 0.03 2.22 · 1025 0.03 1.50 · 1024 0.03 6.14 · 10210 0.0003
cg18942579 17 57915773 VMP1 20.10 1.69 · 1025 20.09 2.99 · 1024 20.10 8.23 · 10210 0.0004
All 65 probes signiﬁcant after Bonferroni correction are listed in Table, Supplemental Digital Content 5, http://links.lww.com/IBD/A561.
aGRCh37/hg19.
bMean beta value for CD relative to the mean beta value for controls.
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the pediatric data, the commonest ﬁnding was of hypomethylation
with increased variance and combining methylation results at 2
probes achieved strong separation between control and disease
groups (see Fig., Supplemental Digital Content 7, http://links.lww.
com/IBD/A563 that shows 2-locus methylation plots for the adult
replication cohort).
Linear Discriminant Analysis
Using the pediatric discovery cohort methylation beta values
as learning set for LDA, models were created for each possible
combination of 2 probes to predict the presence of CD, which were
then tested using the beta values from the pediatric replication
cohort. Area under the curve values for the performance of these
models in the replication cohort ranged from 0.79 to 0.98 (median
0.93). Figure 2A shows the separation in 2-dimensional beta values
by diagnosis in 10 two-probe combinations.
Interpretation and Selection of Genes for
Further Study
To highlight genomic regions for further study, we considered
3 criteria: the signiﬁcance of individual CpGs, clustering of CpGs
into DMRs, and colocalization of methylation changes with risk loci
identiﬁed by GWAS. Genes that scored highly in multiple categories
were given the highest priority for further investigation (Fig. 3), with
VMP1/MIR21 emerging as the strongest candidate. Similarly, the
TNF locus within the HLA region was enriched for highly signiﬁ-
cant methylation changes within a DMR, in a region of established
interest in CD. Other genes of interest include SBNO2 and IL18RAP,
where highly signiﬁcant CpGs are found within risk loci established
by GWAS studies and ZBTB16 and RUNX3, where DMRs contain
or neighbor highly signiﬁcant individual CpGs.
VMP1/MIR21
Five probes within the VMP1/MIR21 locus, 4 of which lie
within a DMR (Fig. 4), had disease-associated changes in meth-
ylation surviving Bonferroni correction. These probes are clus-
tered at the 30 end of VMP1, around the 11th exon, within 50 kb of
a GWAS SNP (rs1292053). The DMR is directly adjacent to the
transcription start site and promoter region for the primary tran-
script of MIR21 (pri-miR-21).
We conﬁrmed CD-associated hypomethylation of this region
in blood by pyrosequencing in 172 adults (P ¼ 6.6 · 1025,
Fig. 5A). The qPCR for pri-miR-21 in 43 adults with CD and 23
healthy controls demonstrated an increase of expression in CD
(P , 0.005, Fig. 5B). Analysis of previously published data34
demonstrated an increased expression of MIR21 (P ¼ 1.4 ·
1026) and VMP1 (P ¼ 2.6 · 1023) in biopsies from inﬂamed
versus uninﬂamed mucosa in CD, which was not observed in con-
trols (Fig. 5C). MIR21 showed signiﬁcantly increased expression in
inﬂamed versus uninﬂamed UC biopsies (5.1 · 1027), but there
was no inﬂammation-related increase in VMP1 expression, unlike
that seen in CD.
DISCUSSION
Principal Findings
This study establishes a signiﬁcant and highly replicable
pattern of DNA methylation associated with pediatric CD, with
further replication in adults for many of the most signiﬁcant
pediatric results. We show a signiﬁcant enrichment of methyl-
ation changes in proximity to GWAS risk loci, offering a novel
approach in exploring the biological variation associated with
common genetic variants and have derived biomarkers, which
show remarkable accuracy in determining the presence of CD.
As such, this study provides an important conﬁrmation of the
validity and feasibility of methylation screening in complex
disease and complements the emerging evidence implicating
epigenetic alterations in IBD and other immune-mediated
diseases and complex traits, such as rheumatoid arthritis,11 obe-
sity,14 and diabetes.13
VMP1 and MIR21
The discovery of methylation alterations within the VMP1/
MIR21 locus emerges as the strongest individual result. Further
conﬁrmation of altered methylation of this region in CD by pyro-
sequencing in adults is augmented with data showing increased
expression of MIR21 in blood in CD and increased expression of
MIR21 in inﬂamed intestinal biopsies in CD but not controls.
TABLE 2. Differently Methylated Regions
Directiona Genes P (Minimum) Chr Coordinateb Length Probes
Y VMP1 1.97 · 10215 17 57915150 1138 4
[ ZBTB16 1.78 · 1029 11 113946633 1241 3
[ SLC15A4 4.58 · 1028 12 129281291 408 3
[ TNF 8.31 · 1028 6 31543764 2126 4
[ DIABLO 1.17 · 1027 12 122711835 306 6
[ ZFYVE28 1.76 · 1027 4 2321442 1151 3
[ RUNX3 2.19 · 1027 1 25291794 351 5
Y HGF 2.44 · 1027 7 81399131 536 3
Y GPR56 6.43 · 1027 16 57662273 536 3
[ TOLLIP 8.18 · 1027 11 1296881 554 3
[ ITGB2 1.21 · 1026 21 46341036 536 3
[ PIEZO1 1.19 · 1026 16 88831961 1086 3
[ PRF1 1.47 · 1026 10 72362714 190 6
[ ZBTB12 2.23 · 1026 6 31867623 330 9
[ PRF1 6.32 · 1026 10 72360292 160 6
[ CD247 7.59 · 1026 1 167486463 1685 4
Y CETP 1.39 · 1025 16 56995572 536 3
[ UBASH3A 1.45 · 1025 21 43823747 1030 3
[ WRAP73 3.21 · 1025 1 3563024 1937 3
aDirection of methylation change.
bCoordinates refer to GRCh37/hg19.
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VMP1 encodes a transmembrane protein located in the Golgi
apparatus, endoplasmic reticulum, and vacuoles with high degrees
of expression in the intestine, kidney, ovary, and placenta.39 There is
high transspecies conservation of VMP1, and it is noteworthy that
expression induces autophagy through interactions with BECN1.40,41
MIR21 was one of the earliest described microRNAs and has
been implicated in numerous cancers, including IBD-associated
colorectal cancer.42 The mature sequence is produced from a pre-
cursor overlapping with the 30 end of VMP1. This region is highly
conserved, exhibits DNase I hypersensitivity and is associated with
the promoter-associated histone marks H3K4Me1 and H3K4Me3.43
MIR21 has a known role in T-cell differentiation and
development.44–47 Increased expression of MIR21 in active IBD
and IBD-associated dysplasia has been described elsewhere,48,49
and MIR21 knockout mice have been shown to be protected from
DSS-induced colitis.50
There is a growing body of evidence for numerous micro-
RNAs being involved in CD such as the regulation of NOD2 by
microRNAs51,52 and NOD2 genotype inﬂuencing IL-23 production
in dendritic cells by regulation of MIR29 production.53 Recent work
has shown ATG16L1 can be regulated by multiple microRNAs,
with resulting effects on autophagy,54,55 particularly interesting
about our data as ATG16L1 contains an MIR21 target motif.56
Other than the VMP1/MIR21 discovery, a number of the other
loci implicated by our study are noteworthy in the context of disease
pathogenesis and will bear further investigation. The data implicating
the HLA region, and, in particular, the TNF locus complement the
genetic data implicating this region in determining IBD susceptibility
and phenotype and the body of evidence implicating TNF in disease.
Other regions that are of great interest to intestinal immune
regulation showing highly signiﬁcant replicable alterations in
methylation in our study include SOCS3, a suppressor of cytokine
signaling to the JAK/STAT pathway,57,58 TOLLIP,59 and
RPS6KA2,60 a ribosomal S6 kinase interacting with MAPkinase1/3.
Linear Discriminant Analysis
DNA methylation of speciﬁc loci has found use as a bio-
marker in diagnosis and prognosis of cancer,61,62 such as methyla-
tion at a tumor suppressor CpG Island. The results of our LDA serve
as a proof of concept for the development of methylation-based
FIGURE 2. A, Separation by diagnosis is achieved by plotting beta values for combinations of 2 Illumina 450k probes with signiﬁcant disease-
associated methylation changes in the discovery cohort. Beta values for both discovery (open) and replication (ﬁlled) cohorts are shown. Area
under the curve for the model based on each probe combination shown in the top right of each panel. B, Replication of disease-associated
methylation changes in 7 signiﬁcant probes by pyrosequencing in 40 adults. HC, healthy controls.
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diagnostic biomarkers in complex diseases. Future work should also
seek to establish prospective links with other clinical outcomes, such
as response to treatment and disease course.
The use of children who required colonoscopy to rule out IBD
as controls precisely models the clinical scenario in which a diagnostic
biomarker would ﬁnd use. CD-speciﬁc methylation patterns weaken
with increased age and were absent in the elderly (data not shown),
possibly due to the accumulation of confounding factors, such as
environmental exposure, comorbidity and polypharmacy, or inherent
effects of aging on methylation.18 It remains to be determined if this
approach is equally pertinent for conditions with a later age of onset.
Strengths and Limitations
This study provides an impetus for further analysis of
alterations of leukocyte DNA methylation in IBD and other
complex diseases, with many targets emerging for further study.
In comparison with GWAS data, we show highly reproducible and
signiﬁcant disease-associated methylation changes using a modest
number of samples. Indeed, the strength and reproducibility of our
ﬁndings compare favorably with epigenetic data generated to date in
IBD and other complex diseases10,11,63 and also with the results of
theoretical modeling based on predicted disease-associated methyl-
ation patterns. In particular, the magnitude and variance of observed
methylation changes in whole blood contrasts with models used to
predict required group sizes (see Fig., Supplemental Digital Content
8, http://links.lww.com/IBD/A564, shows power to detect methyl-
ation changes similar to VMP1/MIR21).9 These data may inform
future study design in IBD and other complex diseases.
FIGURE 3. Schema for the selection of targets for further study,
showing examples and total numbers for each set. GWAS risk loci
correspond to all CD and IBD results from recent GWAS meta-analysis,1
inclusion within epigenome-wide signiﬁcance and differentially
methylated regions sets based on individual probe signiﬁcance sur-
viving Bonferroni correction, and being identiﬁed as a DMR by the
modiﬁed ChAMP algorithm, respectively (Methods). VMP1/MIR21
shown at the intersection of all 3 sets.
FIGURE 4. A, The signiﬁcance of disease-associated methylation changes in all Illumina 450k probes in VMP1. A schematic representation of the gene
is overlaid (bars represent exons, lines represent introns), the height of which corresponds to a Bonferroni corrected P, 0.05. B, Expanded view of the
30 end of VMP1 in (A), with MIR21 primary transcript (line) and mature MIR21 (bar) plotted below. C, Beta values for each sample, colored by diagnosis,
at all Illumina 450k probes across VMP1 (excluding the unmethylated 50 CpG island). Background shading highlights probes contained in the DMR.
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In designing this study, we addressed the key confounding
issues relevant to epigenome analysis, which are currently subject
to intensive scientiﬁc debate. Our approach of basing the study
initially in pediatric disease has been successful in generating data
replicable in children and adults. Studies in children have the
advantage of reducing the inﬂuence of age, comorbidity, poly-
pharmacy, smoking, and environmental factors, which could
confound epigenetic changes. The focus on circulating leukocytes
in IBD rather than intestinal mucosa in this study is strongly
supported by scientiﬁc evidence of immune dysregulation, the well-
recognized clinical extraintestinal manifestations, and indeed the
recent evidence of an encouraging response to autologous bone
marrow transplant in refractory disease.64 Methylation at numerous
sites has also been shown to inﬂuence PBMC response to stimu-
lation of toll-like receptors ex-vivo with multiple ligands.16 Ease of
access to blood is clearly advantageous in biomarker discovery.
The heterogeneity of studied tissues is a commonly cited
concern in epigenome-wide analysis.65 We demonstrated the ability to
use genome-wide methylation data with contemporaneous clinical full
blood count data to correct for whole-blood heterogeneity. If such data
are not available, comparison with reference methylation data sets29,66
from separated cells and alternative techniques67 has been demon-
strated effective and accurate. These strategies are feasible for trans-
lational studies, especially high throughput clinical investigations,
where cell separation adds considerable processing and expense.
Our data are highly signiﬁcant even after applying Bonfer-
roni correction for multiple testing—this correction that is widely
applied in GWAS studies is likely to emerge as overly conserva-
tive in the context of EWAS because it ignores the correlation of
methylation between neighboring probes. The establishment of
a consensus on the limit of epigenome-wide signiﬁcance for
DNA methylation arrays remains a priority for future reporting
of epigenetic ﬁndings in complex diseases.
Although the combined factors of moderate study size and
conservative correction for multiple testing may well contribute to
false negatives (type II error), the reproducibility in 3 independent
cohorts and level of statistical signiﬁcance provide a high degree of
conﬁdence in our positive ﬁndings. Parallels may be drawn with the
early linkage and association studies in IBD, which allowed modeling
of the genetic architecture and delivered “low-hanging fruit” in terms
of NOD2 and HLA associations,68–70 ﬁndings that have subsequently
been unequivocally replicated in large scale experiments.
The emerging evidence of a role for MIR21 in IBD from
other approaches enhances the biological plausibility of this
ﬁnding and strengthens the case for using EWAS in CD and
other complex diseases to discover novel biologically signiﬁcant
genes. Moreover, the enrichment of methylation differences near
to genetic risk loci variants seen in these data and previous
work38,71 raises the possibility that epigenetic modiﬁcations may
help identify speciﬁc points within large genetic susceptibility loci
where genetic and biological variation overlap.
There is at present intense interest in the application of
epigenomic analyses in complex diseases, and technologies and
analytic approaches are evolving rapidly. The strengths and
limitations of the approach are becoming better understood,
leading to the very real hope that EWAS will now evolve to
complement GWAS in understanding pathogenesis. To date,
methylation proﬁling has been limited by the application of
FIGURE 5. A, Replication of VMP1/MIR21 hypomethylation at cg16936953 by pyrosequencing of the same region in 172 adults. B, Increased
leukocyte MIR21 primary transcript in CD measured by qPCR (n ¼ 66). C, Microarray data34 showing signiﬁcantly increased pri-miR-21 mRNA in
response to inﬂammation in CD and UC. VMP1 increased in CD, but not UC or control.
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analytic approaches developed for genetic rather than epigenomic
analysis. In cases, this has led to overestimating the strength of
results, such as failing to appreciate the bias introduced by the wide
variety of probe numbers per gene in pathway analysis.37 However,
failing to appreciate the difference between a SNP of limited pos-
sible states weakly correlated with disease risk, and the bounded
continuous variable of DNA methylation has led to underestima-
tions of the power of moderate-scale epigenetic studies.
CONCLUSIONS
Overall, these observations serve to highlight the need to
integrate methylation, genetic, and expression data in future studies
of the pathogenesis of complex diseases and provide insight into
potential mechanisms involved in gene-environmental interaction.
There are exciting and immediate implications for early clinical
translation; the discovery of easily accessible biomarkers in
peripheral blood to predict disease susceptibility, progression or
response to therapy, and the potential for new therapeutic targets.
Future studies should evaluate altered methylation and
expression at these sites, including MIR21, both in whole blood
and speciﬁc cell types, before initiation of disease and in association
with environmental factors to better understand causality.
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